Penrose, through unprecedented tissue-driven pharmacologic insights, has pioneered a next-generation class of Mitochondrial Modifying Agents (MMA), which create a selective mitochondrial vulnerability that ultimately lead to cancer cell metabolic collapse. Since mitochondria are essential bioenergetic, biosynthetic, and signaling factories that are critical for cancer cell survival and growth, we’re going straight to the epicenter of cancer cell survival, killing them from the inside out.